National Institute for Health and Care Excellence

NICE proposes adding cytisine to stop-smoking guideline

The NICE consultation on cytisinicline follows NHS England's announcement that varenicline would be available again for NHS patients as a generic.…

NICE may be ‘systematically undervaluing’ medicines for severe conditions, says ABPI

The Association of the British Pharmaceutical Industry is urging the government and National Institute for Health and Care Excellence to “show greater flexibility when assessing medicines for severe conditions”.…

Everything you need to know about NICE’s decisions on ‘game-changing’ Alzheimer’s drugs

In August and October 2024, the National Institute for Health and Care Excellence issued a decision not to recommend two new drugs for Alzheimer’s disease that experts had previously welcomed for their disease-modifying effects. We explain the reasons behind their decisions.…

NICE recommends cognitive behavioural therapy for treatment of menopause symptoms

The guidance says menopause-specific cognitive behavioural therapy can be used in addition to hormone replacement therapy or as an alternative.…

Statin prescribing in England at record high, show NICE data

Figures show that atorvastatin prescribing increased from 4.2 million people in 2022/2023 to 5.0 million people in 2023/2024.…

NICE overturns decision on blood cancer treatment elranatamab

Elranatamab is now recommended as a fourth-line treatment for relapsed and refractory multiple myeloma, according to updated guidance from the National Institute for Health and Care Excellence.…

NICE rejects second Alzheimer’s disease treatment for NHS use

Clinical trial evidence reveals that there are “significant health risks” linked to donanemab, with a third of patients experiencing amyloid-related imaging abnormalities as a result of brain swelling and bleeding.…

NICE lifts restrictions on myeloma treatment teclistamab in final draft guidance

The updated guidance recommends the monoclonal antibody for anyone with relapsed or refractory multiple myeloma who has received three or more lines of treatment and whose myeloma has progressed.…

Weight loss drug pilot rollout ‘paused’ in England, says Obesity Health Alliance

A report by the Obesity Health Alliance also revealed waiting lists for overweight and obesity management services were “routinely reaching three to five years”.…

More than 1.5 million people could be given tirzepatide for weight loss under NHS proposals

Priority will be given to patients with the highest clinical need, identified as those with a BMI of more than 40 and at least three specific weight-related health problems.…